Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM CHLORIDE versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM CHLORIDE versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 IN PLASTIC CONTAINER.
POTASSIUM CHLORIDE vs POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride dissociates to provide potassium ions and chloride ions. Potassium repletion corrects hypokalemia and associated disorders.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction, and cardiac function. Dextrose provides a source of calories and may enhance cellular potassium uptake via insulin-mediated shift.
Oral: 40-100 mEq/day in divided doses; IV: up to 10-20 mEq/hour via central line, max 40 mEq/hour with continuous monitoring; not to exceed 200 mEq/day.
Intravenous infusion; typical adult dose: 10-20 mEq per hour, not exceeding 40 mEq per dose and 200 mEq per day, titrated based on serum potassium and ECG monitoring.
None Documented
None Documented
Clinical Note
moderateQuinidine + Potassium chloride
"Quinidine may increase the ulcerogenic activities of Potassium chloride."
Clinical Note
moderateTrimethaphan + Potassium chloride
"Trimethaphan may increase the ulcerogenic activities of Potassium chloride."
Clinical Note
moderateMecamylamine + Potassium chloride
"Mecamylamine may increase the ulcerogenic activities of Potassium chloride."
Clinical Note
moderateAtracurium besylate + Potassium chloride
Not applicable; potassium is an electrolyte regulated by homeostasis, not classic elimination half-life. Under normal renal function, serum half-life of administered potassium is approximately 2-4 hours due to rapid cellular uptake and renal excretion.
The terminal elimination half-life of potassium is approximately 1-1.5 hours in individuals with normal renal function. This reflects rapid redistribution and renal clearance. In anephric or oliguric patients, half-life is prolonged significantly, leading to accumulation and risk of hyperkalemia. Dextrose has a half-life of 15-20 minutes due to rapid cellular uptake and metabolism.
Primarily renal (90%) as potassium ion; minimal fecal (<10%) and sweat.
Renal excretion accounts for approximately 90% of potassium elimination, primarily via distal tubular secretion and reabsorption. Fecal excretion is minimal (<10%). The dextrose component is completely metabolized to CO2 and water, with no direct renal excretion.
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement
"Atracurium besylate may increase the ulcerogenic activities of Potassium chloride."